Articles by Jeanette Barone

Amylyx Supports Rare Disease Day® and #ShowYourStripes Campaign to Raise Awareness for Rare Disease Communities February 22, 2021

#ShowYourStripes In Community Solidarity by Using New Facebook Filter or Downloadable Video Conferencing Background Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative diseases, has joined forces with the National Organization for Rare Disorders (NORD®) to help raise awareness for this year’s Rare Disease Day® on February 28 th . Rare Disease Day is an annual awareness day dedicated to elevating public understanding of rare diseases and emphasizing the special challenges the community faces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005597/en/ #ShowYourStripes Video Conferencing Background Available for Download (Graphic: Business Wire) Amylyx is honored to be a Rare Disease Day “Campaign Supporter” and participate in NORD’s #ShowYourStripes campaign, which aims to empower advocates,

Read More
Amylyx Pharmaceuticals Announces Publication of CENTAUR Survival Data Demonstrating Statistically Significant Survival Benefit of AMX0035 for People with ALS October 16, 2020

Data From CENTAUR Trial Published in Muscle & Nerve Demonstrates That Administration of AMX0035 Results in Longer Survival for People With ALS Early Administration of AMX0035 Reduced the Risk of Death by 44% Over the Duration of Follow-Up AMX0035 is the First ALS Therapeutic to Demonstrate Both a Statistically Significant Survival and Functional Benefit in ALS in a Randomized Controlled Trial Majority (77%) of Patients Were Receiving One or More Approved ALS Therapies at or Before Study Entry Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced the publication of an overall survival analysis from the CENTAUR trial evaluating AMX0035 in people with ALS in the neuromuscular disease journal Muscle & Nerve . The survival analysis followed each CENTAUR participant for up to three years from the start of the trial regardless of

Read More

Stay Connected

Get the latest news and updates from Amylyx, delivered right to your inbox.

By clicking SUBMIT, you confirm that you have read Amylyx's Privacy Policy and that you agree to receive the electronic communications from Amylyx that you've selected. You can withdraw your consent at any time.

Stay Connected

Get the latest news and updates from Amylyx, delivered right to your inbox.

By clicking SUBMIT, you confirm that you have read Amylyx's Privacy Policy and that you agree to receive the electronic communications from Amylyx that you've selected. You can withdraw your consent at any time.